Evidence map›Paper›PMID 36446771›Full record

Trial reportBlood cancer journal2022

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.

Karthik Ramasamy, Gulnaz Iqbal, Richard Brouwer, Victoria Stalker, Salma Akhtar, Sherin Varghese, Jindriska Lindsay, Stephen Schey, Mark Drayson, Janet Dunn

Open access · goldAbstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Karthik Ramasamy *Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. karthik.ramasamy@ndcls.ox.ac.uk.ORCID 0000-0003-3385-3707
Gulnaz Iqbal *Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
Richard BrouwerChurchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Victoria StalkerChurchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID 0000-0001-5157-7043
Salma AkhtarChurchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Sherin VargheseChurchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Jindriska LindsayEast Kent Hospitals University Trust, Canterbury, Kent, UK.
Stephen ScheyKing's College Hospital NHS Foundation Trust, London, UK.
Mark DraysonDivision of Immunity & Immunotherapy, University of Birmingham, Birmingham, UK.ORCID 0000-0002-1528-7564
Janet DunnWarwick Clinical Trials Unit, University of Warwick, Coventry, UK.
Churchill Hospital · GBUniversity of Warwick · GBEast Kent Hospitals University NHS Foundation Trust · GBKing's College Hospital NHS Foundation Trust · GBUniversity of Birmingham · GB

Funding

Bloodwise 13023
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsMultiple MyelomaRenal InsufficiencyBendamustine HydrochlorideBortezomibDexamethasoneHumansThalidomideBendamustine HydrochlorideBortezomibDexamethasoneThalidomide

Identifiers

PMID36446771
PMCPMC9708638
OpenAlexW4310207270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.